Clinical trial
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With…
NCT00288561 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00288561 |
|---|---|
| Title | Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration |
| Official title | Open-Label, Multicenter, Phase II Study Assessing the Safety of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Occult or Predominately Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (ARMD) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Age-Related Macular Degeneration (ARMD) |
| Intervention type | Drug |
| Interventions | ranibizumab |
| Start date | Nov 1, 2004 |
| Completion | Jul 1, 2007 |
| First posted | Feb 8, 2006 |
| Last update posted | Jun 19, 2008 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: